KR20240054264A - Heteroaryl compounds for treating huntington's disease - Google Patents

Heteroaryl compounds for treating huntington's disease Download PDF

Info

Publication number
KR20240054264A
KR20240054264A KR1020247003414A KR20247003414A KR20240054264A KR 20240054264 A KR20240054264 A KR 20240054264A KR 1020247003414 A KR1020247003414 A KR 1020247003414A KR 20247003414 A KR20247003414 A KR 20247003414A KR 20240054264 A KR20240054264 A KR 20240054264A
Authority
KR
South Korea
Prior art keywords
pyrrolo
triazol
phenol
fluoro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247003414A
Other languages
English (en)
Korean (ko)
Inventor
수레쉬 바부
라우풀 알람
아누라다 바타차리야
광밍 첸
매튜 에스. 이스트우드
세예드모르테자 호세이니
야오 장
게리 미첼 칼프
문영춘
자나 나라심한
홍규 렌
나디야 시도렌코
매튜 지. 울
난징 장
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20240054264A publication Critical patent/KR20240054264A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020247003414A 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease Pending KR20240054264A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203761P 2021-07-30 2021-07-30
US63/203,761 2021-07-30
PCT/US2022/038870 WO2023009816A1 (en) 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
KR20240054264A true KR20240054264A (ko) 2024-04-25

Family

ID=83149486

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003414A Pending KR20240054264A (ko) 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease

Country Status (16)

Country Link
US (1) US20240336613A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024528066A (cg-RX-API-DMAC7.html)
KR (1) KR20240054264A (cg-RX-API-DMAC7.html)
CN (1) CN118159539A (cg-RX-API-DMAC7.html)
AR (1) AR126612A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022320725A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227287A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000250A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000890A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240043A (cg-RX-API-DMAC7.html)
IL (1) IL310440A (cg-RX-API-DMAC7.html)
MX (1) MX2024001417A (cg-RX-API-DMAC7.html)
PE (1) PE20240929A1 (cg-RX-API-DMAC7.html)
TW (1) TW202321247A (cg-RX-API-DMAC7.html)
WO (1) WO2023009816A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1142380S1 (en) * 2024-12-31 2026-08-18 Samsung Electronics Co., Ltd. Monitor

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3249778A1 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP2022525417A (ja) * 2019-03-15 2022-05-13 スカイホーク・セラピューティクス・インコーポレーテッド 異常スプライシングを修正するための組成物および方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1142380S1 (en) * 2024-12-31 2026-08-18 Samsung Electronics Co., Ltd. Monitor

Also Published As

Publication number Publication date
CR20240043A (es) 2024-05-22
CO2024000890A2 (es) 2024-04-29
MX2024001417A (es) 2024-05-14
EP4377317A1 (en) 2024-06-05
JP2024528066A (ja) 2024-07-26
CL2024000250A1 (es) 2024-07-12
PE20240929A1 (es) 2024-04-30
US20240336613A1 (en) 2024-10-10
AR126612A1 (es) 2023-10-25
CA3227287A1 (en) 2023-02-02
AU2022320725A1 (en) 2024-02-22
CN118159539A (zh) 2024-06-07
IL310440A (en) 2024-03-01
WO2023009816A1 (en) 2023-02-02
TW202321247A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
US12103926B2 (en) Compounds for treating huntington's disease
EP3814357B1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3969446B1 (en) Compounds for treating huntington's disease
CN118159539A (zh) 用于治疗亨廷顿氏病的杂芳基化合物
JP7799618B2 (ja) ハンチントン病を処置するための化合物
KR20250034045A (ko) 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
EA051950B1 (ru) Гетероарильные соединения для лечения болезни хантингтона
HK40116823A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
NZ794019A (en) Compounds for treating huntington's disease
EA041957B1 (ru) Соединения для лечения болезни гентингтона
US20240132509A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40043148B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40043148A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000